prikaz prve stranice dokumenta A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
  Preuzmi
PDF 2.37 MB
Znanstveni rad - Prikaz slučaja
A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
BMC Infectious Diseases, 19 (2019), 1; https://doi.org/10.1186/s12879-019-3768-y
Skuhala, Tomislava; Atelj, Anita; Prepolec, Jelena; Al-Mufleh, Mahmoud; Stanimirović, Andrija; Vukelić, Dalibor

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Skuhala, T., Atelj, A., Prepolec, J., Al Mufleh, M., Stanimirović, A. i Vukelić, D. (2019). A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage. BMC Infectious Diseases, 19. (1). doi: 10.1186/s12879-019-3768-y

Skuhala, Tomislava, et al. "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage." BMC Infectious Diseases, vol. 19, br. 1, 2019. https://doi.org/10.1186/s12879-019-3768-y

Skuhala, Tomislava, Anita Atelj, Jelena Prepolec, Mahmoud Al Mufleh, Andrija Stanimirović i Dalibor Vukelić. "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage." BMC Infectious Diseases 19, br. 1 (2019). https://doi.org/10.1186/s12879-019-3768-y

Skuhala, T., et al. (2019) 'A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage', BMC Infectious Diseases, 19(1). doi: 10.1186/s12879-019-3768-y

Skuhala T, Atelj A, Prepolec J, Al Mufleh M, Stanimirović A, Vukelić D. A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage. BMC Infectious Diseases [Internet]. 07.02.2019. [pristupljeno 09.11.2024.];19(1). doi: 10.1186/s12879-019-3768-y

T. Skuhala, A. Atelj, J. Prepolec, M. Al Mufleh, A. Stanimirović i D. Vukelić, "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage", BMC Infectious Diseases, vol. 19, br. 1, Veljača 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:211515. [Citirano: 09.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:211515
Podaci o radu
Naslov (engleski)A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
AutorTomislava Skuhala
AutorAnita Atelj
AutorJelena Prepolec
AutorMahmoud Al-Mufleh
AutorAndrija Stanimirović
AutorDalibor Vukelić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: Tumor necrosis factor-α (TNF-α) antagonists, most of which are monoclonal antibodies, became a widespread treatment for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, psoriasis, psoriatic arthritis, hidradenitis suppurativa and uveitis. Their use is based on the blockage of TNF-α, which plays an important role in granulomas formation, development of phagosomes, activation and differentiation of macrophages, immune response against viral pathogens. The multiple adverse effects of TNF-α inhibition have been identified, including a two-to four-fold increased risk of active tuberculosis and other granulomatous conditions and an increased occurrence of some other serious bacterial, fungal and certain viral infections. ----- CASE PRESENTATION: A 34-year-old male patient with disseminated varicella and pneumonitis was admitted to our hospital. The diagnosis of varicella was established serologically by enzyme immunoassay (EIA) and by polymerase chain reaction confirmation of the virus in vesicular fluid. The patient has been receiving adalimumab and methotrexate for the last 3 years due to ankylosing spondylitis and was seropositive to varicella zoster virus prior to the introduction of TNF-α antagonists. Acyclovir was administered for 10 days with the resolution of clinical illness and radiological signs of pneumonitis. CONCLUSION: Due to the use of biological agents, particularly TNF-α inhibitors, as a well-established therapy for some autoimmune diseases, new potential adverse events can be expected in the future and we wanted to point out one of them. To our knowledge this is the first case of recurrent disseminated varicella in a patient taking TNF-α antagonists.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBMC Infectious Diseases
Brojčani podacivol. 19, br. 1
p-ISSN1471-2334
DOIhttps://doi.org/10.1186/s12879-019-3768-y
URN:NBNurn:nbn:hr:105:211515
Datum objave publikacije2019-02-07
URL dokumentahttp://doi.org/10.1186/s12879-019-3768-y
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:28:44